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Highlights
• The study demonstrates the benefits of using functionalized small-diameter biodegradable vascular 
graft for de novo vascular tissue formation. 
• The release of growth factors and chemoattractant molecules into the vascular bed after the graft 
implantation stimulates neotissue formation and levels out inflammation and calcification.
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Background
Currently, the search for the bioactive molecules capable of promoting formation 
of the vascular tissue is still ongoing. We have previously demonstrated that 
incorporation of the growth factors and chemoattractant molecules into the 
biodegradable tubular scaffolds can increase their primary patency upon the 
implantation into rat abdominal aorta. However, further studies are required to 
investigate tissue remodeling using functionalized vascular grafts with the same 
diameter as a replaced native vessel.
Aim
To investigate the specific aspects of de novo vascular tissue formation and 
calcification employing rat abdominal aorta interposition model and vascular 
grafts with 1.5 mm diameter with incorporated vascular endothelial growth factor 
(VEGF), basic fibroblast growth factor (bFGF), and stromal cell-derived factor 
(SDF)-1α.
Methods
Tubular grafts with a diameter of 1.5 mm were blended of poly(3-hydroxybutyrate-
co-3-hydroxyvalerate) and poly(ε-caprolactone) (PHBV/PCL). Grafts without 
growth factors were fabricated using standard electrospinning technique whilst 
grafts with incorporated growth factors were prepared utilizing emulsion 
electrospinning. VEGF was incorporated into the inner third, whereas bFGF 
and SDF-1α were incorporated into the outer two-thirds of the graft. Grafts 
were implanted into the abdominal aortas of Wistar rats for 1, 3, 6, and 12 
months following scanning electron microscopy along with histological and 
immunofluorescent examination. 
Results
Primary patency of the grafts with VEGF, bFGF, and SDF-1α reached 93% 
indicative of structural integrity of the vascular tissue. Neither signs of inflammation 
nor severe calcification was detected.
Conclusion
As in 2 mm diameter vascular grafts, incorporation of bioactive factors into 1.5 
mm diameter grafts increased their long-term primary patency and improved 
vascular tissue formation in comparison with non-modified grafts.
Keywords Biodegradable polymers • Vascular grafts • Electrospinning • Growth factors • 
Chemoattractants • Biological activity
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Background
High prevalence of coronary artery disease and 
peripheral artery disease leads to a high demand for 
small-diameter vascular prostheses suitable for surgical 
revascularization. Tissue engineering of small diameter 
blood vessels has become a promising approach for 
generating alternatives to autologous vascular grafts 
[1]. Therefore, the development of a functionalized 
biodegradable vascular prosthesis allowing neovessel 
formation is of paramount importance [1]. We have 
previously demonstrated that the incorporation of 
growth factors and chemoattractant molecules directly 
into the electrospun tubular polymeric scaffold with 
2 mm diameter may enhance its angiogenesis [2, 3]. 
Potential benefits of the layered incorporation of several 
growth factors and chemoattractant molecules into 
the scaffold and their influence on the cells have been 
shown [4]. The incorporation of vascular endothelial 
growth factor (VEGF) into the inner third, and the basic 
fibroblast growth factor (bFGF) and chemoattractant 
molecule SDF-1a into the outer 2/3 of the graft wall may 
stimulate the formation of the endothelial and smooth 
muscle layers and enhance 100% patency noted at 12 
months after their implantation into the vascular bed of 
small laboratory animals. The technology of imparting 
nanoscale internal surfaces to improve adhesion 
and further vital activity of mature and progenitor 
endothelial cells has been tested in the grafts with three 
biologically active molecules. But the small number of 
the implanted grafts in the previous experiments (n = 
4), the mismatch between the diameters of the rat aorta 
(ø 1.2 mm) and the graft itself (ø 2.0 mm) point specific 
gaps in evidence and set challenges for vascular 
tissue remodeling using biodegradable scaffolds with 
improved morphology of the internal surface that we 
addressed in the current study.
The aim of the study was to assess specific aspects 
of vascular neotissue formation and calcification 
evidenced from the long-term implantation of 
biodegradable vascular grafts with 1.5 mm dimeter 
and incorporated VEGF, bFGF and the chemoattractant 
molecule SDF-1a.
 
Methods
Fabrication of functionalized polymeric tubular 
scaffolds
Tubular matrices with 1.5 mm diameter containing 
a complex of biologically active molecules (GFmix) 
were fabricated by a two-phase electrospinning (Nanon-
01A, MECC, Japan) at a voltage of 23 kV, a solution 
feeding rate of 0.5 ml / h and 1.5 mm rotating drum 
diameter from the composite suspension prepared from 
a mixture of  5% polyhydroxybutyrate / valerate (PHBV, 
Sigma-Aldrich, USA) and 10% polycaprolactone 
(PCL, Sigma-Aldrich, USA) dissolved in chloroform 
and a solution of biomolecules in phosphate buffered 
saline (PBS). Recombinant rat growth factors (vascular 
endothelial growth factor (VEGF, Sigma-Aldrich, 
USA), basic fibroblast growth factor (bFGF, Sigma-
Aldrich, USA) and the recombinant rat chemoattractant 
molecule SDF-1α (Sigma-Aldrich, USA) were used 
as biologically active molecules for the incorporation 
into the matrices. Biologically active molecules were 
dissolved in the polymer solution at a ratio of 20 : 1. 
The final concentration of biomolecules was 500 ng/
ml. The inner 1/3 of the scaffold wall was made from 
the composite suspension of PHBV/PCL and VEGF 
at 20 : 1 ratio using a 27G needle to produce more 
nano-sized polymer filaments on the inner surface of 
the grafts. Then, the electrospinning was continued 
using a 22G needle through which an emulsion of the 
PHBV/PCL solution with bFGF and SDF-1α equally 
diluted in PBS at a final ratio of 20: 1 was fed. The final 
concentration for each biomolecule was 500 ng/ml in 
the polymer solution.
Unmodified biodegradable PHBV/PCL scaffolds 
were fabricated with electrospinning from a 5% 
polyhydroxybutyrate / valerate mixture (PHBV, Sigma-
Aldrich, USA) and 10% polycaprolactone (PCL, 
Sigma-Aldrich, USA) dissolved in chloroform without 
introducing a liquid phase with biologically active 
molecules in the following mode: applied voltage of 
23 kV, solution feeding rate of 0,5 ml / h and rotating 
drum diameter of 1,5 mm. 
In vivo implantation
6-month-old male Wistar rats weighing 400-450 g 
(n = 120) were used to implant biodegradable vascular 
grafts. All procedures were carried out in accordance 
with the principles of the European Convention for the 
protection of vertebrate animals used for experimental 
and other scientific purposes (Strasbourg, 1986). All 
animals received 3% isoflurane anesthesia which 
was then maintained with a concentration of 1.5% 
isoflurane. Vascular grafts with a diameter of 1.5 mm 
and a length of 10 mm after sterilization by γ-irradiation 
were implanted into the rat abdominal aorta by end-
to-end anastomosis. All surgical procedures were 
performed under sterile conditions. After surgery, all 
animals were returned to free access of food and water. 
Rats with implanted grafts were withdrawn from the 
experiment at 1, 3, 6 and 12 months (n = 15 at every 
control point; the total number of the PHBV/PCL/
GFmix grafts implanted to the study group was 60, 
the total number of the PHBV/PCL grafts implanted 
to the control group was 60). Polymeric vascular grafts 
were isolated from the adjacent aorta and divided 
into two parts. One part was frozen at -140 °C for the 
subsequent immunofluorescent analysis. The second 
part was fixed in 10% buffered formalin (Electron 
Microscopy Sciences) for 24 hours at 4 °C for the 
histological assessment. Three grafts from both group 
at each control point underwent scanning electron 
microscopy to assess endothelization of the inner graft
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 surface and conduct elemental analysis.
Histological examination
The implanted samples were fixed in formalin 
for 24 hours, then washed in running tap water, and 
dehydrated in a graded series of alcohols for 5 hours, 
then cleared in xylene for 1 hour and in pure xylene 
for 1 hour. The samples in a mixture of xylene-paraffin 
were placed in a thermostat overnight (for 16-18 hours) 
at 37 °C. Impregnation of the samples with paraffin 
wax (3 portions) was performed at 56 °C for 30 – 40 
minutes. Impregnated samples were poured into paraffin 
HISTOMIX (BioVitrum, Russia). All the samples were 
glued on the block. The embedded samples were cut into 
8-μm-thick using a conventional microtome (model HM 
325, Thermo Scientific, USA). The samples were then 
placed in a thermostat and dried overnight at 37 °C. After 
complete drying of the samples, they were dewaxed in 
o-xylene (3 portions) for 1-2 min and rehydrated in 96% 
alcohol (3 portions) for 1-2 min.
Hematoxin-eosin staining required the dewaxed 
sections to be washed in distilled water and placed in 
a Hariss’ hematoxylin solution (BioVitrum, Russia) 
for 15 min, followed by the washing with water for 
3-10 min. Subsequently, the sections were immersed 
in a solution of eosin (BioVitrum, Russia) for 0.5 min, 
washed in water for 1 min, dehydrated in a graded 
series of alcohols for 1 min, and cleaned in xylene for 
3 min under control. Sections were mounted onto the 
microscope glasses using the mounting medium.
For Van-Gieson staining, the dewaxed sections were 
washed in water and placed in Weigert’s hematoxylin 
(BioVitrum, Russia) for 2 minutes, then washed in 
water until bleaching was achieved. The sections were 
stained with picrofuxin (BioVitrum, Russia) for 2-3 
minutes, then washed in running tap water, dehydrated 
in a graded series of alcohols up to 5 minutes, cleaned 
in xylene for several minutes under control while 
bleaching. Sections were mounted onto the microscope 
glasses using the mounting medium.
Elastin staining was performed using commercially 
available kits («Orsein», BioVitrum, Russia). The 
dewaxed sections were placed in distilled water, 
then treated with 5 drops of potassium permanganate 
solution and 5 drops of activating acid buffer for 
4 minutes. After that the sections were rinsed with 
distilled water and treated with 10 drops of oxalic acid 
for 1 min. After bleaching, the sections were washed 
twice in distilled water. 20 drops of the alcohol reagent 
were added to provide the moist chamber. The sections 
were placed in the container, after being treated with 
10 drops of Shikata’s orcein, closed and incubated for 
30 minutes. The sections were then rinsed in distilled 
water. Finally, they were treated with 10 drops of the 
differentiating solution for 2 min and rinsed in running 
tap water for 1 min, dehydrated, cleaned and mounted 
onto the microscope glasses. After that the samples 
were studied with light microscopy using the AXIO 
Imager A1 microscope (Carl Zeiss, Germany).
Calcification assessment
We assessed the presence of amorphous calcium or 
its crystalline fractions using the sections cut from the 
explanted PHBV/PCL and PHBV/PCL/GFmix grafts 
with the diameter of 1.5 mm which were stained with 
alizarin red C (Himservice, Russia) and DAPI (Sigma-
Aldrich, USA). In addition, the sections of the PHBV/
PCL/VEGF, PHBV/PCL/bFGF, and PHBV/PCL/SDF-
1a grafts with the diameter of 2 mm, which long-term 
patency has been reported previously in [3, 5], and the 
sections of the non-woven PHBV/PCL/VEGF, PHBV/
PCL/bFGF, PHBV/PCL/SDF-1a matrices, the respond 
to their subcutaneous implantation has been studied in 
[6], underwent the similar staining procedure for the 
assessment. They were then immersed in a 2% aqueous 
solution of alizarin red C for 70 seconds, then nuclei of 
cells were stained with DAPI 10 μg/ml for 3 minutes. 
The specimens were then washed with distilled water, 
and dried. Cover slips were used to keep the specimens 
in place. After that, all specimens underwent light and 
fluorescence microscopy using the AXIO Imager A1 
microscope (Carl Zeiss, Germany) with ×50, ×100 and 
×200 magnifications.
Immunofluorescent staining
The tissue sections of 8 μm thickness from the 
frozen samples were cut with a cryotome Microm HM 
525 Cryostat (Thermo Scientific, USA) and mounted 
on poly-L-lysine coated glasses. Immunofluorescent 
staining of the sections was performed using the 
following primary antibodies: mouse anti-rat CD31 
(ab119339, Abcam) and rabbit anti-CD34 (ab185732, 
Abcam), or anti-rat collagen type I antibodies 
(ab28028, Abcam) and rabbit anti rat collagen type 
IV antibodies (ab6586, Abcam), or von Willebrand 
factor antibody conjugated to FITC (ab8822, Abcam). 
If unconjugated primary antibodies were used, then 
a mixture of secondary antibodies was applied: goat 
anti-mouse Ig antibodies, AlexaFluor568 conjugate 
(ab175473, Abcam),and donkey anti-rabbit Ig 
antibodies, AlexaFluor488 conjugate (ab150105, 
Abcam). Autofluorescence was removed with the 
Autofluorescence Eliminator Reagent (Millipore, 
USA) according to the manufacturer’s instructions. 
The sections were stained with DAPI (Sigma-Aldrich, 
USA) and mounted onto the labeled glasses with the 
ProLong mountant (Life Technologies, USA). Native 
rat aorta was used as a positive control for anti-CD31 
and anti-vWF staining whereas rat embryo was used 
as a positive control for anti-CD34 staining, and rat 
skin sections for collagen I and IV. Negative controls 
were performed by replacing primary antibodies with 
BSA-PBS while following the staining protocol. The 
specimens were then analyzed with LSM 700 Confocal
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Laser Scanning Microscope (Carl Zeiss, Germany).
Scanning electron microscopy
Endothelialization of the internal surface of the 
explanted vascular grafts was assessed with scanning 
electron microscopy. First, the samples were fixed 
with 1% glutaraldehyde (Sigma-Aldrich, USA) for 1.5 
hours, and then postfixed with 1% osmium tetroxide 
(Serva Electrophoresis, Germany) in 0.1 M phosphate 
buffer for 3 hours. Further, the samples were dehydrated 
in a graded series of alcohols by 15 min incubation 
with 30% to 90% and twice by 30 min incubation at 
100%. The samples from both groups were mounted 
on special tables, then the ion-sputtered method was 
employed to form conductive coating (gold-palladium 
coating) using the Emitech SC 7640 (Quorum 
Technologies, England). The surface of the samples 
was assessed with a scanning electron microscope 
(S-3400N, Hitachi, Japan) under high vacuum mode 
at an accelerating voltage of 5 kV in the secondary 
electrons imaging.
Statistical analysis
Statistical analysis was performed using GraphPad 
Prism (GraphPad Software). A sampling distribution 
was assessed by the Kolmogorov–Smirnov test. 
Two independent groups were compared by Mann–
Whitney U-test. More than three independent groups 
were compared using Kruskal–Wallis test, and the 
Dunn’s t-test was used for a pairwise comparison. P 
of ≤0.05 were regarded as statistically significant. Data 
are presented as the median and the 25th and 75th 
percentiles of Me (25%, 75%). 
Results
All the animals with the PHBV/PCL implanted 
grafts survived up to the withdrawal from the 
experiment. Histological examination reported that 
33.3% (5 out of 15) and 26.7% (4 out of 15) of the 
PHBV/PCL grafts had thrombi partially occluding the 
graft lumen. There were no signs of the neointima and 
endothelial layer formation (Fig. 1). Only 66.7% (10 
out of 15) and 73.3% (11 out of 15) of the PHBV/PCL 
grafts were 100% patent within 1 and 3 months after 
the implantation. However, the high cellularity of the 
PHBV/PCL graft walls reported at 1 month developed 
into moderate granulomatous wall inflammation in 
26.7% of the implanted grafts (4 of 15), and moderate 
neointimal hypertrophy in one case (6.7%, 1 out of 15) 
within the 3-months implantation period (Fig. 1). A 
very thin interrupted neointimal layer proliferated on 
the inner surface in the rest of the samples. Single cells 
with the transitional phenotypes CD31+, CD34+ were 
found within 1 month after the implantation, whereas 
a discontinuous layer of endothelial cells with the 
transitional phenotypes CD31+, CD34+ synthesizing 
von Willebrand factor was determined within 3 months 
after the implantation (Fig. 2).
Collagen fibers were detected in the graft walls and 
in the outer capsule (Fig. 1). Collagen type IV was 
represented by separate inclusions on the inner surface 
of the grafts (Fig. 2). There were no elastin fibers found 
(Fig. 1).
All animals who underwent the PHBV/PCL/GFmix 
graft implantation survived over the 1- and 3-months 
implantation period. All the PHBV/PCL/GFmix 
samples (15 out of 15) were 100% patent according to 
the findings of the morphological examination (Fig. 3).
The inner surface of the grafts was covered with a 
thin neointimal layer, which further thickened in the 
zones with calcium crystals within 3 months after the 
implantation. The graft neointimal surface was covered 
with the interrupted endothelial layer containing cells 
with the transitional phenotypes CD31+, CD34+ 
at 1 month. It suggests the active involvement of 
hematopoietic progenitor cells attached to the graft 
surface from the blood flow, which then differentiated 
into mature endothelial cells and actively expressed 
the von Willebrand factor (Fig. 4). 3 months after 
the implantation, the neointimal layer in the PHBV/
PCL/GFmix grafts was covered with a continuous 
or interrupted endothelial layer with the phenotypes 
CD31+, and CD34-, actively secreting von Willebrand 
factor (Fig. 4). A layer of collagen type IV was formed 
(Fig. 4).
Type I and IV collagen fibers were defined in the 
graft walls and the outer capsule as well. None elastin 
fibers were found (Fig. 3, 4). There were no signs of 
granulomatous inflammation (Fig. 3).
Two animals from the PHBV/PCL group died within 
2 – 2.5 weeks before the 6-months control point. The 
cause of death in both cases was the graft thrombosis, 
accompanied by lower extremity ischemia. When the 
rest animals were withdrawn from the experiment, 
the thrombus was found in one more case. It almost 
occluded the graft lumen. Thus, the 6-months rate of 
thrombosis was 20.0% among the PHBV/PCL grafts 
(3 out of 15). 80.0% of the PHBV/PCL grafts (12 out 
of 15) were patent. However, anterior wall aneurysms 
were found in 13.3% (2 out of 15) of cases. 46.7% 
(7 out of 15) of the samples demonstrated moderate 
granulomatous wall inflammation, which did not 
interfere in the formation of the elements of the newly 
formed vascular tissue, but visually increased the 
cellularity of the graft wall (Fig. 1). The inner surface 
of the PHBV/PCL grafts was covered with a thin 
semilunar neointimal layer or had uniformly thin layer. 
However, the neointima thickened in the zones of the 
calcium crystal deposits (Fig. 1).
At 6 months control point, all PHBV/PCL/GFmix 
grafts (15 out of 15) were patent (Fig. 3). Histological 
examination reported that the inner lumen of each 
graft was lined with a thin neointimal layer covered 
with endothelium. There were no signs of neointimal
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 Figure 1. Histological examination of the non-modified PHBV/PCL vascular grafts (1.5 mm 
diameter) implanted into rat abdominal aorta at 1, 3, 6, and 12 months
Figure 2. Immunofluorescent examination of the non-modified PHBV/PCL vascular grafts (1.5 mm diameter) implanted into 
the rat abdominal aorta for 1, 3, 6, and 12 months. vWF staining of endothelial cells (green, х200); CD31 staining of mature 
endothelial cells (red, x630) and CD34 staining of endothelial progenitor cells (green, x630); DAPI staining of nuclei (blue); 
collagen IV (green, x200) and collagen I (red, x200) staining of extracellular matrix
hyperplasia. Neointima thickened in the zones of 
the calcium crystal deposits. The cellularity and the 
development of the connective tissue of the graft wall 
were moderate and more pronounced in the outer 2/3 
of the graft wall (Fig. 3). The inner surface of the 
modified and non-modified grafts was covered with a 
layer of mature endothelial cells with the phenotypes 
CD31+, CD34-, vWF+ (Fig. 2, 4). The layer in the 
PHBV/PCL grafts was intermittent, whereas in the 
PHBV/PCL/GFmix grafts it was continuous. A well-
defined layer of type IV collagen was detected under 
the endothelium. In addition, the inclusions of type I 
and IV collagen were found in the graft wall as well 
(Fig. 2, 4).
1 animal from the PHBV/PCL group died 6 
months before the 12-months control point due to 
the graft thrombosis, which was accompanied by 
lower extremity ischemia. 4 more grafts had thrombi 
according to the histological and immunofluorescent 
analyses. Thus, 33.3% of the PHBV/PCL grafts (5 out
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Figure 3. Histological examination of the PHBV/PCL vascular grafts (1.5 mm diameter) with incorporated 
bioactive factors (VEGF, bFGF, and SDF-1α) implanted into the rat abdominal aorta at 1, 3, 6, and 12 months
Figure 4. Immunofluorescent examination of the PHBV/PCL vascular grafts (1.5 mm diameter) with incorporated bioactive 
factors (VEGF, bFGF, and SDF-1α) implanted into the rat abdominal aorta at 1, 3, 6, and 12 months. vWF staining of endothelial 
cells (green, х200); CD31 staining of mature endothelial cells (red, x630) and CD34 staining of endothelial progenitor cells 
(green, x630); DAPI staining of nuclei (blue); collagen IV (green, x200) and collagen I (red, x200) staining of extracellular matrix
of 15) had thrombi almost occluding the entire graft 
lumen after the 12-months implantation period. These 
grafts had reduced wall cellularity, no endothelium 
and none calcium crystal deposits (Fig. 5). However, 
66.7% of the PHBV/PCL grafts (10 out of 15) were 
patent (Fig. 1), but 33.3% of them (5 out of 15)
had moderate granulomatous wall inflammation, 
accompanied by a large number of foreign cell bodies, 
which, however, did not lead to the narrowing of the 
graft lumen and preventing of the neointima formation, 
compared to polycaprolactone used for manufacturing 
a tubular biodegradable scaffold [7]. Due to moderate 
granulomatous wall inflammation, the cellularity of 
the non-modified graft walls was visually higher than 
those in the GFmix grafts. Therefore, the difference in 
the number of cells in the non-modified and modified
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graft walls suggests the absence of any advantages 
associated with the non-modified substitutes, but, 
vice versa, states the problem of an unfavorable 
cellular response to their implantation. The semilunar 
neointimal layer covered with endothelial cells was 
found in all grafts (Fig. 1). Neointimal hypertrophy 
was observed only in the areas with calcium deposits 
(Fig. 1). Anterior wall aneurisms were found in 13.3% 
of the grafts (2 out of 15) after their explantation.
All animals from the PHBV/PCL/GFmix group 
survived up to the end of the experiment. Histological 
and immunohistochemical studies of the explanted 
specimens reported that 93.33% of the PHBV/PCL/
GFmix grafts (14 out of 15) were absolutely patent 
(Fig. 2). However, 1 graft had an obturating recanalized 
thrombus occluding the graft lumen. The cellularity of 
the graft walls was moderate and more pronounced 
in the outer 2/3 of the walls. There were no cases of 
granulomatous wall inflammation, compared to the 
non-modified specimens (Fig. 2).
The inner surface of the PHBV/PCL/GFmix grafts 
was covered with a thin neointimal layer with a 
monolayer formed by mature endothelial cells CD31+, 
CD34-, vWF+ (Fig. 4), whereas an endothelial layer 
on the inner surface of the PHBV/PCL grafts was 
intermittent and contained both mature endothelial cells 
CD31+, CD34-, vWF+ and cells with the transitional 
phenotypes CD31+, CD34+, vWF+. It suggested 
that the last endothelial layer was instable and was 
constantly renewing (Fig. 4). The subendothelial layer 
of collagen type IV as well as type I and IV collagen 
fibers were found in the graft walls and outer capsules 
of the grafts from both groups (Fig. 2, 4). There were 
no elastin fibers found at 12 months (Fig. 1, 3).
3 months after the implantation, the deposits of 
the amorphous and crystalline calcium were first 
determined in the PHBV/PCL grafts, regardless of 
the presence or absence of the modification. Thus, 
46.7% of the patent PHBV/PCL grafts (7 out of 15) 
had amorphous and crystalline calcium foci under the 
neointimal layer: from single foci to up to ½ of the graft 
circumference (Fig. 5). One small focus was detected 
only in 6.7% (1 out of 15) of the studied specimens, 
while extended deposits up to 1/6 to 1/2 of the graft 
circumference were found in 40.0% of the studied 
grafts (6 out of 15). The focal deposits of fine-grained 
crystals of calcium have been determined in 20.0% of 
the PHBV/PCL/GFmix grafts (3 out of 15) (Fig. 5). 
80.0% of the grafts (12 out of 15) were free of the 
calcium deposits.
In order to determine the possible pathway of the 
graft calcification, all grafts with calcium deposits 
were further divided into 2 groups either with the 
predominant Ca deposits in the zone of anastomoses 
propagating to the central part of the graft wall or 
uniform Ca deposits along the entire length of the graft, 
including anastomoses. Only one graft (6.7%, 1 out of 
15) had calcium-enriched anastomosis zone, whereas 
40.0% of the studied grafts (6 out of 15) had uniform 
distribution of Ca throughout the entire length of the 
graft. Importantly, 4 patent (26.7%) and 4 thrombosed 
(26.7%) grafts did not have any calcium deposits.
6 months after the implantation, there were no 
calcium deposits in the failed grafts (20.0% of the total 
number, 3 out of 15) and in 20.0% of the patent PHBV/
PCL grafts (3 out of 15). 60.0% (9 out of 15) of the non-
modified grafts demonstrated the deposits of calcium 
crystals, semilunar or rounded, spread up to 1/10 - 1/2 of
Figure 5. Light and fluorescence microscopy of the non-modified PHBV/PCL vascular grafts and PHBV/PCL vascular grafts with 
incorporated bioactive factors after combined alizarin red S and DAPI staining for calcium (red) and nuclei (blue), respectively
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the graft circumference (Fig. 5). Nevertheless, calcium 
deposits in the anastomosis zone and around the suture 
material prevailed in 13.3% (2 out of 15) of the studied 
grafts, whereas calcium deposits throughout the graft 
length were found in 46.7% of the PHBV/PCL grafts 
(7 out of 15).
There were no Ca deposits in 20.0% of the 
explanted PHBV/PCL/GFmix grafts (3 out of 15) 
within 6 months after the implantation. 80.0% of the 
grafts had calcific walls and anastomoses. The more 
pronounced calcification of the anastomosis zones 
was found in 13.3% of the PHBV/PCL/GFmix grafts 
(2 out of 15), including Ca deposits around the suture 
material (Fig. 5). 66.7% of the grafts (10 out of 15) had 
uniform calcification throughout the entire length and 
in the zones of anastomoses. Importantly, one small 
Ca site in the graft wall was detected in 46.7% of the 
studied grafts (7 out of 15), and two or more foci, or the 
distribution of crystalline calcium up to 1.8 of the graft 
circumference was determined in 33.3% of the PHBV/
PCL/GFmix grafts (5 out of 15). Thus, the grafts with 
single Ca foci prevailed in the modified group within 6 
months after the implantation.
12 months after the implantation, the failed grafts 
did not have any signs of calcification among the 
PHBV/PCL grafts. Large-grained crystals of calcium 
were detected in all patent grafts (Fig. 5): 13.3% of the 
grafts (2 out of 15) had one large focus of crystalline 
calcium underneath the neointimal layer, and 53.3% 
of the grafts (8 out of 15) had semilunar deposits 
of crystalline calcium from 1/8 to ½ of the graft 
circumference, or multiple individual foci along the 
entire circumference under the neointimal layer. 26.7% 
of the grafts (4 out of 15) had large Ca deposits in the 
anastomosis zones, whereas 40.0% of the grafts (6 out 
of 15) had heavy calcification throughout the entire 
length of the grafts, including anastomoses.
There were no signs of calcification in 26.7% of the 
patent PHBV/PCL/GFmix grafts (4 out of 15) and in 
6.67% of the failed PHBV/PCL/GFmix grafts (1 out of 
15) within 12 months after the implantation. Two patent 
grafts without any signs of the wall calcification had 
Ca deposits mainly around the suture material in the 
anastomosis zones (Fig. 5). 66.7% patent PHBV/PCL/
GFmix grafts (10 out of 15) had crystalline Ca located 
underneath the neointimal layer (Fig. 5). The size and 
extent of the calcium deposits varied significantly from 
single small foci to the severe calcification throughout 
the entire graft length. One small focus was found in 
26.7% of the grafts (4 out of 15), whereas 40.0% of the 
PHBV/PCL/GFmix grafts (6 out of 15) had several and 
large deposits.
The layered cutting performed in 26.7% of the 
PHBV/PCL/GFmix grafts (4 out of 15) allowed 
tracing the pattern of calcium distribution from the 
anastomosis zone, where calcium deposits were 
mostly accumulated, to the center of the graft, where 
they were mostly represented by single small foci 
located under the neointimal layer. However, it was 
impossible to determine the vector of Ca spreading into 
the graft stratum in 40.0% of the PHBV/PCL/GFmix 
grafts as the calcium deposits were almost identical in 
various parts of the grafts, ranging from single foci to 
insignificant deposits of amorphous Ca throughout the 
entire graft length.
Scanning electron microscopy of the inner graft 
surface was performed to assess endothelization of 
the explanted vascular grafts with 1.5 mm. 1 month 
after the implantation, the PHBV/PCL/GFmix grafts 
had more pronounced endothelization of the inner 
surface, covering almost the entire studied area. 
Importantly, there were no exposed areas of the 
polymer surface, as in the PHBV/PCL grafts. 3 months 
after the implantation, a continuous endothelial lining 
covered the entire inner surface of the GFmix grafts 
was observed. Its integrity preserved until the end of 
the experiment. The endothelial lining of the non-
modified grafts appeared only within 6 months after the 
implantation and was equal to that in the PHBV/PCL/
GFmix grafts. However, the degree and uniformity of 
the endothelial lining in the area of anastomoses were 
higher in the PHBV/PCL/GFm grafts since they were 
similar to the inner surface of the adjacent segments of 
the native aorta (Fig. 6).
The experiment suggested that calcification 
developed only in the patent grafts. It means that 
blood, being a biological medium saturated with cells 
and calcium, and the blood flow, supports and / or 
provokes the development of calcification processes. 
This assumption is further supported by the fact that 
the failed non-modified and modified PHBV/PCL 
grafts did not have any calcium deposits.
To confirm this assumption that blood as a 
biological medium and blood flow capable to mediate 
mechanotransduction trigger the development of 
prosthesis calcification after its implantation into the 
vascular bed, additional studies were conducted to 
detect calcium in the samples of non-woven matrices 
implanted subcutaneously for a 12-months period (Fig. 
7). Therefore, we analyzed the explanted samples of 
the non-woven PHBV/PCL matrices with incorporated 
VEGF, bFGF and SDF-1a. The tissue reaction to the 
subcutaneous implantation of these matrices has been 
previously discussed in [6]. In addition, we used other 
vascular graft samples with 2 mm diameter containing 
VEGF, bFGF, SDF-1a which were previously implanted 
for a 12-months period in our previous experiments [2, 
3] to assess the impact of the modification approach of 
biodegradable vascular grafts on their calcification. These 
samples were additionally stained with alizarin red and 
DAPI and subjected to fluorescence microscopy (Fig. 7).
We found that there were no calcium deposits 
in the samples of non-woven matrices implanted 
subcutaneously within the 12-months period (Fig. 7).
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Despite the modification approach, calcium crystals 
were found in all explanted samples of the PHBV/
PCL vascular grafts of 2 mm in diameter. The calcium 
crystals were mainly located under the neointimal layer 
and around the suture material (Fig. 7).
Thus, the incorporation of the growth factors and 
chemoattractant molecules into the biodegradable 
tubular scaffolds, at least in an isolated form, does not 
provoke calcification processes that starts in the graft 
wall after their implantation into the vascular bed of 
small laboratory animals. A key role of the blood flow 
in the initiation of calcification processes is indirectly 
evidenced by the results of the 12-month subcutaneous 
implantation of the same matrices and the absence of 
any Ca deposits in the failed grafts.
Discussion
Rapid endothelization, the formation of smooth 
muscle cells and a large number of cells that produce an 
intercellular matrix are the decisive factors that ensure
Figure 6. Scanning electron microscopy of the luminal surface of the non-modified PHBV/PCL vascular grafts and PHBV/PCL 
vascular grafts with incorporated bioactive factors along with an adjacent aortic segment, x500
Figure 7. Light and fluorescence microscopy of 2 mm diameter PHBV/PCL vascular grafts with incorporated bioactive factors upon 
12-month intraaortic and subcutaneous implantation. Combined alizarin red S and DAPI staining for calcium (red) and nuclei (blue), 
respectively
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high primary patency of vascular grafts [8, 9, 10]. 
Importantly, the PHBV/PCL/GFmix grafts were 
100% patent within the 12-months implantation 
period. GFmix contributes to the active sticking of 
precursor cells from the bloodstream to the inner 
surface of the grafts, which led to the formation of 
the mature endothelial cell layer within the 3-months 
implantation period. There was no granulomatous 
wall inflammation in the PHBV/PCL/GFmix grafts. 
However, the cellularity of the grafts was inferior to 
the non-modified substitutes, which may be explained 
with the increased nanostructure of the inner graft 
surface and limited cell migration into the thickness of 
the tubular scaffolds. The similar reason could affect 
the absence of a visible difference in the formation of 
the connective tissue in the modified and non-modified 
grafts represented by type I and IV collagens. The 
total patency of the PHBV/PCL/GFmix vascular grafts 
within the 12-months implantation period was 93.33% 
due to the stable endothelization of the inner graft 
surface in situ. 12 months after the implantation of the 
non-modified PHBV/PCL vascular grafts, there were 
signs of endothelial layer desquamation and endothelial 
population renewal with moderate granulomatous wall 
inflammation observed in 33.3% of the grafts, which 
resulted in the preservation of the primary patency in 
66.7% of the PHBV/PCL grafts.
Pathological calcification of the cardiac structures 
is one of the main challenges of modern medicine. 
Despite the fact that the mechanisms underlying these 
processes are poorly understood [11], researchers 
agree that the initiating factors of calcification include 
endothelial dysfunction, inflammatory reactions 
and oxidative stress, leading to remodeling and 
mineralization of cardiac structures [12, 13]. Recent 
studies have shown that cardiovascular calcification is 
triggered through the activation of cellular processes 
in the presence of an uncontrolled pathological 
environment that cannot be reproduced in the in 
vitro models. Therefore, it limits the opportunities 
to investigate the cause-effect relationships, mostly 
studied by the endpoints of the affected tissues [14, 
15]. Smooth muscle cells are considered to be the main 
source of origin of osteogenic cells in calcified vascular 
lesions [16]. Other data indicate that the occurrence 
of ectopic medial calcifications is associated with 
adventitious cells [17]. Vessel and valve endothelial 
cells serve as a cellular barrier between the blood and 
the main tissue components, but participate in the 
endothelial-mesenchymal transition, playing a key 
role in tissue fibrosis and calcification [18]. In vitro 
and ex vivo studies have established the involvement 
of inflammation in the calcification of both valves and 
vessels [19, 20]. Calcification in these tissues follows 
the accumulation of macrophages, and its final stage 
is accompanied by the induction during inflammation 
[14]. Importantly, a new concept suggesting that 
progenitor cells circulating in the blood under certain 
conditions can exhibit their osteogenic potential and 
promote intimal [21] and valvular calcification [22] has 
recently emerged. It was shown that with increasing 
progression of aortic valve stenosis, the number of 
circulating osteocalcin-positive endothelial progenitor 
cells (CD34 + / OCN +) increased with their subsequent 
accumulation in the calcified aortic valve tissue [22]. 
Thus, this cascade results in the deposition of calcium, 
primarily in the zones with critical stress [14].
The hypothesis of mechanical stress, as a factor 
contributing to the onset of calcification, has been 
confirmed in several studies indicating that the 
accumulation of calcium deposits is mainly associated 
with the areas with increased stress experienced by 
tissues during functioning under pulsatile flow [23]. 
Similar patterns have been described both in clinical 
studies [14] and in in vitro studies [24]. However, some 
researchers state that dynamic stress promotes the 
development of calcification, but it is not its primary 
cause [13]. Suture material may be considered an 
additional factor contributing to the calcification of 
prosthetic substitutes [25], which in our experiments 
was not used for subcutaneous implantation of the non-
woven matrices, but was used for placing anastomoses 
during the implantation of biodegradable vascular 
grafts. Thus, calcification of both cardiac structures 
and implanted devices is more likely to be the end-
product of cellular processes and resultant stresses 
under pulsatile flow.
The comparative analysis of the nature and 
prevalence of calcification of the non-modified and 
modified graft walls, almost a third of the explanted 
grafts showed that the onset of calcification processes 
was triggered by anastomoses and surgical suture 
material. There were no differences in the severity of Ca 
deposits in the various zones among 40% of the grafts. 
However, more severe calcification prevailed in the 
non-modified grafts. 53.3% of the grafts had semilunar 
crystalline calcium deposits located beneath the 
neointima and occupied almost half of circumference 
of the graft wall.
The absence of calcification in both, the non-woven 
PHBV/PCL matrices during subcutaneous implantation 
and thrombosed biodegradable vascular grafts, 
confirms the assumption that blood being an aggressive 
biological medium and pulsatile flow provoke 
calcification of the implanted grafts. An additional 
factor that may also contribute to the onset of the graft 
wall calcification is the process of biodegradation 
accompanied by the activation of cells of the monocyte-
macrophage system, which are actively involved in 
the processes of developing inflammatory response, 
for example, granulomatous inflammation. Graft wall 
biodegradation of the thrombosed and patent PHBV/
PCL vascular grafts is associated with the activity of 
cells of the monocyte-macrophage system and does not
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reliant on the presence or absence of blood flow. 
Therefore, the absence of Ca deposits in the thrombosed 
grafts indicates that cellular reactions accompanying 
biodegradation processes are not involved in the onset 
and maintenance of calcification processes.
Conclusion
Thus, the growth factors and chemoattractant 
molecules incorporated into the 1.5 mm biodegradable 
PHBV/PCL vascular grafts preserve their biological 
activity in the grafts after their implantation into the 
vascular bed of laboratory animals. Promising effects 
of the GFmix impact on the cellular response during 
remodeling of the vascular tissue in situ was confirmed 
by the high primary patency of the PHBV/PCL/GFmix 
grafts within the 12-months implantation period as well 
as complete formation of the newly formed vascular 
tissues in the absence of any signs of granulomatous 
inflammation and a certain decrease in the rate and 
severity of calcification.
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